Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial

NARecruitingINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

October 11, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Ischemic Stroke, Acute
Interventions
OTHER

Conservative SBP Control

No or minimal treatment; if there is a need to treat a patient with a very-high (\>180 mmHg) baseline SBP, then the SBP reduction is 5-10mmHg or a target is 175-180 mmHg

OTHER

Moderate SBP Control

If the patient has a very high (\>180 mmHg) or moderate high (160-180 mmHg) baseline SBP, SBP reduction is 10-20mmHg or a target of160±5 mmHg, which is higher; patients with low-high (150-160 mmHg) baseline SBP will not be treated

OTHER

Intensive SBP Control

SBP reduction by 30-50mmHg or a target of 140±5 mmHg, which is higher

Trial Locations (2)

2000

RECRUITING

The George Institute for Global Health, Sydney

T2N 1N4

RECRUITING

University of Calgary, Calgary

All Listed Sponsors
collaborator

University of Calgary

OTHER

collaborator

Changhai Hospital

OTHER

lead

The George Institute

OTHER